http://www.sutrobio.com
Sutro Biopharma, Inc. Company Intro
Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical stage drug discovery, development and manufacturing company. Using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. It focuses to design therapeutics using potent modalities, including cytokine based immune-oncology (I/O) therapeutics, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidates include STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74, for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa), for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF platform.
Industry
Healthcare
Sutro Biopharma, Inc. Headquaters
310 Utah Avenue
South San Francisco,94080
United States
Sutro Biopharma, Inc. Share price
17 May 2023 13:57 GMT
$5.71
-0.02 (-0.35 %)
Sutro Biopharma, Inc. Market cap
$341.355 M
WMC RANKING
2023
Sutro Biopharma, Inc. # 100
BiotechnologyLatest Sutro Biopharma, Inc. News
19 Sep 2023
Sutro Biopharma Inc. (STRO) names Hans-Peter Gerber as ...
Sutro Biopharma, Inc. (NASDAQ: STRO) announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023.
19 Sep 2023
Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief ...
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs)...
19 Sep 2023
Sutro Biopharma Inc. (STRO) names Hans-Peter Gerber as ...
Sutro Biopharma, Inc. (NASDAQ: STRO) announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023.
WMC Market Score
WMC Market to Revenue Score
Sutro Biopharma, Inc. Market Financials
Revenue, Expenses, Profit
| Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
| Sutro Biopharma, Inc. | USD | $50,230 | $121,116 | $-42,892 | $3,414M | 100 |
| Regeneron Pharmaceuticals, Inc. | USD | $9,197,600 | $3,997,800 | $4,003,800 | $804,390B | 1 |
| Vertex Pharmaceuticals Incorporated | USD | $6,414,881 | $2,617,257 | $2,762,032 | $878,880B | 2 |
| Alexion Pharmaceuticals, Inc. | USD | $6,261,601 | $2,747,200 | $681,800 | $ | 3 |
| Incyte Corporation | USD | $2,702,913 | $2,048,306 | $478,480 | $144,340B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total Sutro Biopharma, Inc. Social Followers vs Top 4 Industry Competitors
Sutro Biopharma, Inc. Post vs Top 4 Industry Competitors
Sutro Biopharma, Inc. Digital Footprint By Size vs Top 4 Industry Competitors
Sutro Biopharma, Inc. Digital Footprint By Change Rate vs Top 4 Industry Competitors
Sutro Biopharma, Inc. WMC Market Score Calculations
| Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
| Sutro Biopharma, Inc. | 0.55 | 0.47 | 0.03 | 0 | 0 | 0 | 0.22 |
| Regeneron Pharmaceuticals, Inc. | 100 | 25.50 | 16.15 | 28 | 0 | 0 | 29.94 |
| Vertex Pharmaceuticals Incorporated | 69.75 | 35.68 | 8.95 | 40 | 0 | 0 | 36.32 |
| Alexion Pharmaceuticals, Inc. | 68.08 | 100 | 100 | 32 | 0 | 0 | 100 |
| Incyte Corporation | 29.39 | 5.03 | 0.04 | 100 | 0 | 0 | 45.31 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge
